Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Clinical Reasoning: A 69-year-old man with leukocytosis and hemorrhagic brain lesions
Scott, Kristin M., Gardner, F., Eidelman, Benjamin H., Rivera, Candido E., Menke, David M. , Barrett, Kevin M. , Gardner, Faithlore P

Neurology | June 30, 2014 | Volume: 83 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000000542 | PMID 24982042 Get It

Laboratory Compliance With the American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Guidelines: A 3-Year Comparison of Validation Procedures
Dyhdalo, Kathryn , Fitzgibbons, Patrick L. , Goldsmith, Jeffery D., Souers, Rhona J., Nakhleh, Raouf E. , Dyhdalo, Kathryn S

Archives of Pathology and Laboratory Medicine | June 30, 2014 | Volume: 138 | Issue: 7 | Pages: 876-884

10.5858/arpa.2013-0731-cp | PMID 24978913 Get It

Context.— The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) published guidelines in 2007 regarding testing accuracy, interpretation, and reporting of results for HER2 studies. A 2008 survey identified areas needing improved compliance. Objective.— To reassess laboratory response to those guidelines following a full accreditation cycle for an updated snapshot of laboratory practices regarding ASCO/CAP guidelines. Design.— In 2011, a survey was distributed with the HER2 immunohistochemistry (IHC) proficiency testing program identical to the 2008 survey. Results.— Of the 1150 surveys sent, 977 (85.0%) were returned, comparable to the original survey response in 2008 (757 of 907; 83.5%). New participants submitted 124 of 977 (12.7%) surveys. The median laboratory accession rate was 14 788 cases with 211 HER2 tests performed annually. Testing was validated with fluorescence in situ hybridization in 49.1% (443 of 902) of the laboratories; 26.3% (224 of 853) of the laboratories used another IHC assay. The median number of cases to validate fluorescence in situ hybridization (n = 40) and IHC (n = 27) was similar to those in 2008. Ninety-five percent concordance with fluorescence in situ hybridization was achieved by 76.5% (254 of 332) of laboratories for IHC − findings and 70.4% (233 of 331) for IHC + cases. Ninety-five percent concordance with another IHC assay was achieved by 71.1% (118 of 168) of the laboratories for negative findings and 69.6% (112 of 161) of the laboratories for positive cases. The proportion of laboratories interpreting HER2 IHC using ASCO/CAP guidelines (86.6% [798 of 921] in 2011; 83.8% [605 of 722] in 2008) remains similar. Conclusions.— Although fixation time improvements have been made, assay validation deficiencies still exist. The results of this survey were shared within the CAP, including the Laboratory Accreditation Program and the ASCO/CAP panel revising the HER2 guidelines published in October 2013. The Laboratory Accreditation Program checklist was changed to strengthen HER2 validation practices.
Diffuse Large B-Cell Lymphoma in an Adolescent Male Presenting as Ureteral Stricture
Jaeger, Christopher , McAlvany, Kelly L., Zingula, Shannon N. , Kramer, Stephen A., Granberg, Candace F. , Jaeger, Christopher D

Case Reports in Radiology | June 29, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-3

10.1155/2014/239345 | PMID 25093138 Get It

Lymphoma may affect the ureter in cases of retroperitoneal involvement. We present a case of an adolescent male found to have non-Hodgkin lymphoma initially presenting as ureteral stricture evident on imaging. He was treated and responded to multiagent chemotherapy with resolution of both the lymphoma and the ureteral stricture. Although rare, non-Hodgkin lymphoma should be included in the differential diagnosis of pediatric patients with noncalculous, idiopathic ureteral strictures.
Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images
Wolz, Robin, Schwarz, Adam J. , Yu, Peng , Cole, Patricia E., Rueckert, Daniel , Raunig, David , Hill, David , Initiative, The Alzheimer's Disease Neuroimaging, Jack, Clifford R. , Initiative, The Alzheimer's Disease Neuroimaging

Alzheimer's & Dementia | June 28, 2014 | Volume: 10 | Issue: 4 | Pages: 430

10.1016/j.jalz.2013.09.014 | PMID 24985688 Get It

AbstractBackgroundLow HCV has recently been qualified by the European Medicines Agency as a biomarker for enrichment of clinical trials in predementia stages of Alzheimer's disease. For automated methods to meet the necessary regulatory requirements, it is essential they be standardized and their performance be well characterized.MethodsThe within‐image and between‐field strength reproducibility of automated hippocampal volumetry using the Learning Embeddings for Atlas Propagation (or LEAP) algorithm was assessed on 153 Alzheimer's Disease Neuroimaging Initiative subjects.ResultsTests/retests at 1.5 T and 3 T, and a comparison between 1.5 T and 3 T, yielded average unsigned variabilities in HCVs of 1.51%, 1.52%, and 2.68%. A small bias between field strengths (mean signed difference, 1.17%; standard deviation, 3.07%) was observed.ConclusionsThe measured reproducibility characteristics confirm the suitability of using automated magnetic resonance imaging analyses to assess HCVs quantitatively and to represent a fundamental characterization that is critical to meet the regulatory requirements for using hippocampal volumetry in clinical trials and health care.
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease
Hill, David , Schwarz, Adam J. , Isaac, Maria , Pani, Luca , Vamvakas, Spiros, Hemmings, Robert , Carrillo, María C. , Yu, Peng , Sun, Jia , Boccardi, Marina , Brewer, James B., Brumfield, Martha A., Cantillon, Marc, Cole, Patricia E., Fox, Nick C. , Frisoni, Giovanni B. , Kelleher, Thomas, Luo, Feng , Novak, Gerald , Maguire, Paul, Meibach, Richard C., Patterson, Patricia, Bain, Lisa J. , Raunig, David , Soares, Holly , Suhy, Joyce, Wang, Huanli , Wolz, Robin, Stephenson, Diane , Boccardi, Marina , Frisoni, Giovanni B. , Beckett, Laurel , Jack, Clifford R. , Maguire, Paul, Sampaio, Cristina , Fox, Nick C

Alzheimer's & Dementia | June 28, 2014 | Volume: 10 | Issue: 4 | Pages: 421

10.1016/j.jalz.2013.07.003 | PMID 24985687 Get It

AbstractBackgroundRegulatory qualification of a biomarker for a defined context of use provides scientifically robust assurances to sponsors and regulators that accelerate appropriate adoption of biomarkers into drug development.MethodsThe Coalition Against Major Diseases submitted a dossier to the Scientific Advice Working Party of the European Medicines Agency requesting a qualification opinion on the use of hippocampal volume as a biomarker for enriching clinical trials in subjects with mild cognitive impairment, incorporating a scientific rationale, a literature review and a de novo analysis of Alzheimer's Disease Neuroimaging Initiative data.ResultsThe literature review and de novo analysis were consistent with the proposed context of use, and the Committee for Medicinal Products for Human Use released an opinion in November 2011.ConclusionsWe summarize the scientific rationale and the data that supported the first qualification of an imaging biomarker by the European Medicines Agency.
APOE ε4 influences β‐amyloid deposition in primary progressive aphasia and speech apraxia
Josephs, Keith A. , Senjem, Matthew L. , Lowe, Val J. , Whitwell, Jennifer L. , Strand, Edythe A. , Duffy, Joseph R. , Machulda, Mary M. , Jack, Clifford R. , Senjem, Matthew L

Alzheimer's & Dementia | June 28, 2014 | Volume: 10 | Issue: 6 | Pages: 630-636

10.1016/j.jalz.2014.03.004 | PMID 24985533 Get It

AbstractBackgroundApolipoprotein E ε4 (APOE ε4) is a risk factor for β‐amyloid deposition in Alzheimer's disease dementia. Its influence on β‐amyloid deposition in speech and language disorders, including primary progressive aphasia (PPA), is unclear.MethodsOne hundred thirty subjects with PPA or progressive speech apraxia underwent APOE genotyping and Pittsburgh compound B (PiB) PET scanning. The relationship between APOE ε4 and PiB status, as well as severity and regional distribution of PiB, was assessed.ResultsForty‐five subjects had an APOE ε4 allele and 60 subjects were PiB‐positive. The odds ratio for a subject with APOE ε4 being PiB‐positive compared with a subject without APOE ε4 being PiB‐positive was 10.2 (95% confidence interval, 4.4–25.5; P < .0001). The APOE ε4 allele did not influence regional PiB distribution or severity.ConclusionAPOE ε4 increases the risk of β‐amyloid deposition in PPA and progressive speech apraxia but does not influence regional β‐amyloid distribution or severity.
Left Atrial Appendage Aneurysm: A Systematic Review of 82 Cases
Aryal, Madan Raj , Hakim, Fayaz A., Ghimire, Sailu, Ghimire, Sushil , Pandit, Anil , Bhandari, Yashoda, Bhandari, Naresh, Pathak, Ranjan , Karmacharya, Paras , Pradhan, Rajesh , Giri, Smith , Karmacharya, Paras

Echocardiography | June 28, 2014 | Volume: 31 | Issue: 10 | Pages: 1312-1318

10.1111/echo.12667 | PMID 24976376 Get It

BackgroundAneurysm of the left atrial appendage is rare. We sought to systematically review the published literature on left atrial appendage aneurysm (LAAA) to address its demographic features, clinical characteristics, treatment, complications, and outcomes.MethodologyA systematic electronic search of Medline, PubMed, and EMBASE for case reports, case series, and related articles of LAAA published from 1962 until July 2013 was carried out. Statistical analysis was done using SPSS version 20.0. Logistic Regression Analysis was used to identify the independent predictors of LAAA‐related thrombus formation and embolism.ResultsEighty‐two cases of LAAA were identified. There was a slight female preponderance and most of the patients presented in their third decades. Palpitation, dyspnea or both were most common clinical symptoms associated with LAAA. Echocardiography was the main diagnostic modality used and the mean size of aneurysm was 7.08 ± 3.03 × 5.75 ± 2.36 cm. Surgical resection of the aneurysm was performed in most patients with favorable results. Systemic embolism and atrial tachyarrhythmias were the two common complications associated with untreated LAAA. Presence of atrial fibrillation/flutter was the only significant predictor of thrombus formation/embolic events.ConclusionAneurysm of left atrial appendage is rare and often an incidental diagnosis during echocardiography. It is important to recognize this entity since it is associated with cardiovascular morbidity and mortality by predisposing to atrial tachyarrhythmia and thromboembolism. Surgical resection is the standard of treatment in the current literature. Medical management is directed toward the treatment of thromboembolism and atrial tachyarrhythmia.
How we manage autologous stem cell transplantation for patients with multiple myeloma
Gertz, Morie A. , Dingli, David , Gertz, Morie A , Dingli, David

Blood | June 28, 2014 | Volume: 124 | Issue: 6 | Pages: 882-890

10.1182/blood-2014-03-544759 | PMID 24973360 Get It

AbstractAn estimated 22 350 patients had multiple myeloma diagnosed in 2013, representing 1.3% of all new cancers; 10 710 deaths are projected, representing 1.8% of cancer deaths. Approximately 0.7% of US men and women will have a myeloma diagnosis in their lifetime, and with advances in therapy, 77 600 US patients are living with myeloma. The 5-year survival rate was 25.6% in 1989 and was 44.9% in 2005. The median age at diagnosis is 69 years, with 62.4% of patients aged 65 or older at diagnosis. Median age at death is 75 years. The rate of new myeloma cases has been rising 0.7% per year during the past decade. The most common indication for autologous stem cell transplantation in the United States is multiple myeloma, and this article is designed to provide the specifics of organizing a transplant program for multiple myeloma. We review the data justifying use of stem cell transplantation as initial management in myeloma patients. We provide selection criteria that minimize the risks of transplantation. Specific guidelines on mobilization and supportive care through the transplant course, as done at Mayo Clinic, are given. A review of the data on tandem vs sequential autologous transplants is provided.
Commentary on: Savall F, Dedouit F, Telmon N, Rouge D. Takotsubo cardiomyopathy in a jeweller following a hold‐up: forensic considerations. J Forensic Sci 2013;58:1648–50.
Luis, Sushil Allen , Luis, Chris R., Pant, Sadip, Menezes, Ritesh G. , Luis, Sushil A, Luis, Sushil A

Journal of Forensic Sciences | June 27, 2014 | Volume: 59 | Issue: 4 | Pages: 1159-1159

10.1111/1556-4029.12495 | PMID 24975435 Get It